Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice

Arthur Silverstein, Anton Dudaev, Maria Studneva, John Aitken, Sofya Blokh, Andrew David Miller, Sofia Tanasova, Noel Rose, John Ryals, Christoph Borchers, Anders Nordstrom, Marina Moiseyakh, Arturo Solís Herrera, Nikita Skomorohov, Trevor Marshall, Alan Wu, R. Holland Cheng, Ksenia Syzko, Philip D. Cotter, Marianna PodzyubanWilliam Thilly, Paul David Smith, Paul Barach, Khaled Bouri, Yehuda Schoenfeld, Eiji Matsuura, Veronika Medvedeva, Ilya Shmulevich, Liang Cheng, Paul Seegers, Yekaterina Khotskaya, Keith Flaherty, Steven Dooley, Eric J. Sorenson, Michael Ross, Sergey Suchkov

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Medical abzymology has made a great contribution to the development of general autoimmunity theory: it has put the autoantibodies (Ab) as the key brick of the theory to the level of physiological functionality by providing such Ab with the ability to catalyze and mediate direct and independent cytotoxic effect on cellular and molecular targets. Natural catalytic autoantibodies (abzymes) while being a pool of canonical Abs and possessing catalytic activity belong to the new group of physiologically active substances whose features and properties are evolutionary consolidated in one functionally active biomolecule. Therefore, further studies on Ab-mediated autoAg degradation and other targeted Ab-mediated proteolysis may provide biomarkers of newer generations and thus a supplementary tool for assessing the disease progression and predicting disability of the patients and persons at risks. This chapter is a summary of current knowledge and prognostic perspectives toward catalytic Abs in autoimmunity and thus some autoimmune clinical cases, their role in pathogenesis, and the exploitation of both whole molecules and their constituent parts in developing highly effective targeted drugs of the future to come, and thus the therapeutic protocols being individualized.

Original languageEnglish
Title of host publicationProgress in Molecular Biology and Translational Science
PublisherElsevier B.V.
DOIs
Publication statusPublished - 1 Jan 2022
Externally publishedYes

Publication series

NameProgress in Molecular Biology and Translational Science
ISSN (Print)1877-1173
ISSN (Electronic)1878-0814

Keywords

  • Biomarker
  • Multimarker-based companion diagnostics
  • Multiple sclerosis
  • Next-generation biomarker
  • Personalized and precision medicine
  • Protein microarrays
  • Rheumatoid arthritis
  • Targeted therapy
  • Western blotting

Fingerprint

Dive into the research topics of 'Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice'. Together they form a unique fingerprint.

Cite this